Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer

Breast Cancer Clinical Trial

— ENCORE305  

Official title:

A Phase 2, Randomized, Double-Blind, Multicenter Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02115594
• Other study ID #: SNDX-275-0305
• Status: Withdrawn
• Phase: Phase 2
• First received: April 4, 2014
• Last updated: October 6, 2014
• Start date: April 2014
• Est. completion date: June 2016

Study information

• Verified date: April 2014
• Source: Syndax Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Preclinical data has demonstrated that entinostat (SNDX-275) can enhance fulvestrant sensitivity in hormone receptor-positive breast cancer in animal models. The addition of entinostat to fulvestrant will provide clinical benefit to patients with locally advanced or metastatic breast when compared to fulvestrant plus placebo. Also, based on previous data, patients exposed to entinostat who demonstrate an elevated level of protein lysine acetylation will have an improved efficacy outcome.

Description:

Entinostat (SNDX-275) inhibits mechanisms of resistance to hormone therapy in breast cancer (BC) cells, thereby prolonging sensitivity of the cells to fulvestrant. Preclinical data has demonstrated that entinostat can enhance fulvestrant sensitivity in hormone receptor-positive BC in animal models. Thus, it is hypothesized that the addition of entinostat to fulvestrant will provide clinical benefit to patients with locally advanced or metastatic BC when compared to fulvestrant plus placebo.

Preliminary data from Phase 2 Study SNDX-275-0301 suggest patients with higher levels of protein lysine acetylation who receive entinostat with exemestane potentially have improved clinical outcomes (e.g., PFS, OS) when compared to patients with lower levels of protein lysine acetylation. Thus, it is hypothesized that patients exposed to entinostat and who demonstrate an elevated level of protein lysine acetylation will have an improved efficacy outcome.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 2016
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patient is a female who is: Postmenopausal OR Pre/perimenopausal and: Received at least one prior hormone therapy in combination with a luteinizing hormone-releasing hormone (LHRH) agonist prior to study entry. Initiated on an LHRH agonist at least 28 days prior to study entry. Demonstrated ovarian estradiol suppression, defined as an estradiol level within postmenopausal ranges per institutional guidelines, within 28 days immediately prior to study entry

• Patient has histologically or cytologically confirmed ER+ and/or progesterone receptor-positive (PR+) BC at initial diagnosis or on subsequent biopsy. With regard to hormone receptor status, staining of =1% cells is considered positive. Receptor status may have been determined at any time prior to randomization and from any site (i.e., primary, recurrent, or metastatic)

• Patient experienced PD within 28 days before initiating study treatment and has been deemed eligible for treatment with fulvestrant

• Patient has evidence of locally advanced or metastatic disease, based on imaging studies (bone scan, CT, MRI) within 28 days before initiating study treatment

• Patient completed any prior radiotherapy =2 weeks prior to receiving the first dose of study treatment and has recovered from any radiation-related toxicity

• Patient may have received 1 prior chemotherapy regimen for metastatic disease provided treatment was completed =3 weeks prior to randomization. Prior chemotherapy in the adjuvant or neoadjuvant setting is also allowed

• Patient is willing and able to provide or assist study personnel in accessing slides from prior biopsies

• Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Patient has the following laboratory parameters: a. Hemoglobin (Hgb) =9.0 g/dL; unsupported platelet count =100×10P9P/L; and absolute neutrophil count (ANC) =1.5×10P9P/L without the use of hematopoietic growth factors; b. Creatinine =2.0 mg/dL; c. Total bilirubin <1.5 x institutional upper limit normal (=3 mg/dL in case of Gilbert's syndrome); d. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =2 x institutional upper limit of normal; unless elevation is due to metastatic disease to the liver, in which case ALT and AST must be within 5.0 x institutional upper limit of normal

• Patient is able to swallow tablets

• Patient is able to understand and give written informed consent and comply with study procedures

Exclusion Criteria:

• Patient has rapidly progressive or life-threatening metastases (visceral crisis)

• Patient has HER2-positive (HER2+) disease, as defined by the 2013 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) recommendations for HER2 testing in BC (see http://www.asco.org/quality-guidelines/recommendations-human-epidermal-growth-factor-receptor-2-testing-breast-cancer), or has unknown HER2 status

• Patient previously received treatment with entinostat or any other HDAC inhibitor, including valproic acid

• Patient has had previous treatment with fulvestrant or other selective estrogen receptor down-regulator (SERD) in the metastatic setting; such treatment may have been given in the adjuvant setting

• Patient has an allergy to benzamide or inactive components of the study drug

• Patient has a history of allergies to any active or inactive ingredients of fulvestrant

• Patient has a concomitant medical condition that precludes adequate study treatment compliance or assessment, or increases patient risk, in the opinion of the Investigator, such as but not limited to:

1. Myocardial infarction or arterial thromboembolic event within 6 months prior to Baseline or severe or unstable angina, New York Heart Association (NYHA) Class III or IV disease (see Appendix 2), or a QTc interval >470 msec.

2. Uncontrolled heart failure or hypertension, uncontrolled diabetes mellitus, or uncontrolled systemic infection

3. Another active cancer (excluding adequately treated basal cell carcinoma or cervical intraepithelial neoplasia [CIN] / cervical carcinoma in situ or melanoma in situ). Prior history of other cancer is allowed, as long as there is no active disease within the prior 5 years

• Patient is currently receiving treatment with any agent listed on the prohibited medication list such as valproic acid or other systemic cancer agents

• Patient initiated oral bisphosphonates within 7 days prior to study drug

• Patient has moderate or severe hepatic impairment (i.e., Child-Pugh score B or C)

• Patient has brain or leptomeningeal metastases

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Fulvestrant

• Entinostat

• Placebo

Locations

Country	Name	City	State
United States	Tennessee Oncololgy	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Syndax Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Analysis of biopsy tumor tissue (fresh optional, archival required)	molecular classification of breast cancer (BC) subtypes, DNA methylation, e-cadherin levels, protein lysine acetylation levels, and changes in proteins associated with estrogen signaling and fulvestrant resistance	Screening (fresh tissue) and post 1st dose, between Days 15-18 of study treatment	No
Primary	Progression Free Survival	Radiological disease assessments	From date of randomization until the date of 1st documented progression or date of death from any cause, whichever occurs first, assessed for up to 48 months	No
Secondary	Objective Response Rate (CR or PR)	Radiological disease assessments	From date of randomization until the date of 1st documented progression or date of death from any cause, whichever occurs first, for up to 48 months	No
Secondary	Clinical Benefit Rate (CR, PR, or SD for greater than or equal to 6 months from randomization)	Radiological disease assessments	From the date of randomization until the date of 1st documented progression or date of death, from any cause, whichever occurs first, assessed for up to 48 months	No
Secondary	Overall Survival		From the date of randomization until date of death, assessed for up to 48 months	No
Secondary	Clinical review of safety parameters (AEs, lab values)		From date of randomization until 30 days post the date of study treatment discontinuation	Yes
Secondary	Percent change from baseline in blood protein lysine acetylation measures		From the baseline visit through the 1st 15 days of study treatment	No
Secondary	Concentrations of entinostat measured in plasma (PK)		From the baseline visit through the 1st 15 days of study treatment	No